Skip to content

Linda J Bristow

3 papers in the library · 5 citations · publishing 2017-2025

Papers

Sort Most recent Most cited

5-HT1B receptor activation produces rapid antidepressant-like effects in rodents.

Pharmacology, Biochemistry, and Behavior February 1, 2025 Erin A Clark, Lien Wang, Taleen Hanania et al. 5 citations

Ketamine is noted for its rapid onset antidepressant response and effectiveness in patients with treatment resistant depression. While most research has focused on glutamatergic mechanisms, recent studies show that antidepressant-like effects in rodents are dependent upon the serotonergic (5-HT) system and suggest a potential contribution of the 5-HT1B receptor. In this study we utilized...

DOI: 10.1016/j.pbb.2024.173917 (opens in new tab) Full text (opens in new tab) Synaptic plasticity 5-ht1b receptor agonist Lateral habenula circuit Rapid onset +5

Mapping the central effects of (±)-ketamine and traxoprodil using pharmacological magnetic resonance imaging in awake rats.

Journal of Psychopharmacology February 2018 Haiying Tang, Daniel Kukral, Yu-Wen Li et al.

Major depressive disorder is a leading cause of disability globally. Improvements in the efficacy of antidepressant therapy are needed as a high proportion (>40%) of individuals with major depressive disorder fail to respond adequately to current treatments. The non-selective N-methyl-D-aspartate receptor channel blocker, (±)-ketamine, has been reported to produce a rapid and long-lasting...

Preclinical Characterization of (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one (BMS-986169), a Novel, Intravenous, Glutamate N-Methyl-d-Aspartate 2B Receptor Negative Allosteric Modulator with Potential in Major Depressive Disorder.

Journal of Pharmacology and Experimental Therapeutics December 2017 Linda J Bristow, Jyoti Gulia, Michael R Weed et al.

(R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one (BMS-986169) and the phosphate prodrug 4-((3S,4S)-3-fluoro-1-((R)-1-(4-methylbenzyl)-2-oxopyrrolidin-3-yl)piperidin-4-yl)phenyl dihydrogen phosphate (BMS-986163) were identified from a drug discovery effort focused on the development of novel, intravenous glutamate N-methyl-d-aspartate 2B receptor...